Showing 828 results
-
Media Release /Three leading US cardiology societies have jointly issued a clinical practice guideline update that has redefined standard of care treatment for heart failure and given Entresto® a strong Class I…
-
Media Release /Novartis has established FortiHFy, the largest global clinical program in the heart failure disease area, comprising over 40 active or planned clinical studies designed to generate an array of…
-
Media Release /-- Subject to approvals, Ilaris® (canakinumab) will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF-- Designations support…
-
Media Release /- Global survey, including more than 1,400 U.S. moderate-to-severe psoriasis patients, is the first to look at perceptions of clear skin1- Despite the significant impact of living with the disease,…
-
Media Release /Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors)(1)Cardiology experts highlight risk of…
-
Media Release /- Data demonstrate at 12 months, 81% of patients started on fingolimod stay on therapy vs. 29% started on injectable disease-modifying therapies (iDMTs)(1)- Injectable disease-modifying therapies are…
-
Media Release /-- EXPAND study data presented at ECTRIMS 2016 show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs. placebo in patients with…
-
Media Release /- In a well-controlled, randomized, open-label study, Gilenya patients had higher treatment retention rates at one year, 81.3% vs. those on injectable DMTs, 29.2% - Throughout the study almost 10…
-
Media Release /-- Extension of indication makes Xolair the first and only approved biologic for pediatric patients six years and older with uncontrolled moderate to severe persistent allergic asthma-- Asthma is one…
-
Media Release /-- New data at EADV show Cosentyx delivers almost clear or completely clear skin in majority of patients (PASI 90 - 66%, PASI 100 - 44%) after four years of treatment1-- Data show that with Cosentyx…
